The study investigated the effects of canagliflozin (CAN) on insulin-dysregulated (ID) horses. The research aimed to determine the impact of CAN on insulin sensitivity, insulin clearance, and β-cell responsiveness. Twenty privately owned ID mares participated in a randomized, double-blind, placebo-controlled trial. Horses were administered either CAN (0.4 mg/kg once daily) or a placebo for four weeks. Assessments were conducted using a euglycemic hyperinsulinemic clamp (EHC) to measure insulin sensitivity and insulin metabolic clearance rate (MCR), and a graded glucose infusion test (GGI) to evaluate β-cell responsiveness. Results indicated that insulin sensitivity (M/I) was lower with CAN compared to the placebo group (1.5 ± 0.2 mg/kg/min × 103 / [μIU/mL] versus 2.7 ± 0.2 mg/kg/min × 103 / [μIU/mL]); the least squares mean difference was -1.3 [95% CI, -1.9 to -0.6]; P < 0.001). Conversely, insulin MCR was significantly higher in the CAN group (6.5 ± 0.3 mL/kg/min versus 5.4 ± 0.3 mL/kg/min); the least squares mean difference was 1.0 [95% CI, 0.3-1.8]; P = 0.01). Furthermore, β-cell responsiveness (ΔI versus ΔG) was 43.3% lower with CAN (20.8 [95% CI, 16.9-25.5] mIU/mmol versus 36.7 [29.9-45.1] mIU/mmol); the ratio of geometric least squares means was 0.57 [95% CI, 0.42-0.76]; P < 0.001). The study concluded that β-cell responsiveness was reduced and insulin clearance was increased in the CAN-treated horses, despite apparent lower insulin sensitivity. The research suggests that higher endogenous glucose production in the CAN-treated mares may have contributed to an underestimation of insulin sensitivity.